Methodological considerations for the development of new treatments for bipolar disorder

Australian and New Zealand Journal of Psychiatry

Volumn 33, Issue SUPPL., 1999, Pages

  Potter, William Z ^a   Ozcan, M Erkan ^b  

^a ELI LILLY AND COMPANY   (United States)

^b INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Bipolar disorder; Clinical target; Lithium; Methodology; Mood stabilisers

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DESIPRAMINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; NEUROLEPTIC AGENT; NEW DRUG; TOPIRAMATE; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VALPROIC ACID;

ADVERSE DRUG REACTION; AFFECTIVE NEUROSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; HUMAN; MANIA; MANIC DEPRESSIVE PSYCHOSIS; PATIENT COMPLIANCE; RECURRENT DISEASE; RELAPSE; REVIEW;

AFFECT; ANTIMANIC AGENTS; BIPOLAR DISORDER; DRUG DESIGN; DRUG EVALUATION; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 0033390727     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.1999.033006000.x     Document Type: Review

References (79)

1. Cade JFJ. Lithium suits in the treatment of psychotic excitement. Medical Journal of Australian 1949; 14:349-352.
2. Schou M. Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. Journal of Neurology Neurosurgery and Psychiatry 1954: 17:250-260.
3. Baastrup PC, Schou M. Lithium as a prophylactic agent. Archives of General Psychiatry 1967; 16:162-172.
4. Gershon S, Soares JC. Current therapeutic profile of lithium. Archives of General Psychiatry 1997; 54:16-20.
5. Bowden CL, Swann AC, Calabrese JR et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium placebo study. Psychopharmacology Bulletin 1997; 33:693-699.
6. Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - A randomised study. Journal of Affective Disorders 1997; 43:151-161.
7. Moncrieff J. Lithium: evidence reconsidered. British Journal of Psychiatry 1997; 171:113-119.
8. Manji HK, McNamara R, Chen G. Lenox RH. Signalling pathways in the brain: Cellular transduction of mood stabilisation in the treatment of manic-depressive illness. Australian and New Zealand Journal of Psychiatry 1999; 33:S65-S83.
9. Dunner DL. Lithium carbonate: maintenance studies and consequences of withdrawal. Journal of Clinical Psychiatry 1998; 59 (Suppl. 6):48-55.
10. Goodwill FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press. 1990.
11. Winokur G, Clayton PJ, Reich T. Manic Depressive Illness. St. Louis, MO: CV Mosby Company, 1969.
12. Dunner DL, Murpy D, Stallone F et al. Episode frequency prior to lithium treatment in bipolar manic-depressive patients. Comprehensive Psychiatry 1980; 20:511-515.
13. Srinath S, Janardhan Reddy YC, Girimaji SR, Seshadri SP, Subbakrishna DK. A prospective study of bipolar disorder in children and adolescents from India. Acta Psychiatrica Scandinavica 1998; 98:437-442.
14. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilising survival data analysis. Archives of General Psychiatry 1990; 47:1106-1111.
15. Keller MB, Lavori PW, Coryell W, Endicott J, Mueller TI, Bipolar 1. A 5-year prospective follow-up. Journal of Nervous and Mental Disease 1993; 181:238-245.
16. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. American Journal of Psychiatry 1995; 152:1635-1640.
17. Calabrese JR, Rapport DJ, Mood stabilisers and the evolution of maintenance study designs in bipolar I disorder. Journal of Clinical Psychiatry 1999; 60 (suppl. 5):5-13.
18. Prien RF, Potter WZ. NIMH workshop report on treatment of bipolar disorder. Psychopharmacology Bulletin 1990; 26: 409-427.
19. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993; 27:138-145.
20. Maj M. Clinical prediction of response to lithium prophylaxis in bipolar patients: a critical update. Lithium 1992; 3:15-21.
21. Winokur G, Coryell W, Keller M, Endicott J, Akiskal H. A prospective follow-up of patients with bipolar and primary unipolar affective disorder. Archives of General Psychiatry 1993; 50:457-465.
22. Gelenberg AJ, Kane JM, Keller MB et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. New England Journal of Medicine 1989; 321:1489-1493.
23. Swann AC, Bowden CL, Morris D et al. Depression during mania: treatment response to lithium or divalproex. Archives of General Psychiatry 1997; 54:37-42.
24. Bowden CL. Brugger AM, Swann AC et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. Journal of American Medical Association 1994; 271:918-924.
25. Swann AC, Stokes PE, Casper R et al. Hypothalamicpituitary-adrenocortical function in mixed and pure mania. Acta Psychiatrica Scandinavica 1992; 85:270-274.
26. Post RM, Uhde TW, Roy Byrne PP, Joffe RT. Correlates of antimanic response to carbamazepine. Psychiatry Research 1987; 21:71-83.
27. Cassidy F, Forest K, Murry E, Carroll BJ. A factor analysis of the signs and symptoms of mania. Archives of General Psychiatry 1998; 55:27-32.
28. Vestergaard P, Wentzer Licht R, Brodersen A et al. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatrica Scandinavica 1998; 98:310-315.
29. Strober M, DeAntonio M, Schmidt-Lackner S, Freeman R, Lampert C, Diamond J. Early childhood attention deficit hyperactivity disorder predicts poorer response to acute lithium therapy in adolescent mania. Journal of Affective Disorders 1998; 51:145-151.
30. Schon M. Forty years of lithium treatment. Archives of General Psychiatry 1997; 54:9-13.
31. Tondo L, Baldessarini RJ, Hennen J, Floris G. Lithium maintenance treatment of depression and mania in bipolar I and Bipolar II disorders. American Journal of Psychiatry 1998; 155:638-645.
32. Tondo L, Baldessarini RJ. Floris G, Rudas N. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and Bipolar II disorders. American Journal of Psychiatry 1997; 154:548-550.
33. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar disorders. Archives of General Psychiatry 1993; 50:448-455.
34. Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. Journal of Affective Disorders 1989: 17:237-241.
35. Engstrom C, Astrom M, Nordqvist-Karlsson B, Adolfsson R, Nylander P. Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Biological Psychiatry 1997; 42:425-433.
36. Strakowski SM, Keck PE, McElroy SL et al. Twelve-month outcome after a first hospitalisation for affective psychosis. Archives of General Psychiatry 1998; 55:49-55.
37. Keck PE, McElroy SL, Strakowski SM et al. 12-month outcome of patients with bipolar disorder following hospitalisation for a manic or mixed episode. American Journal of Psychiatry 1998; 155:646-652.
38. Coryell W, Turvey C, Endicott J et al. Bipolar I affective disorder: predictors of outcome after 15 years. Journal of Affective Disorders 1998; 50:109-116.
39. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Archives of General Psychiatry 1991; 48:1082-1088.
40. Post RM, Leverich GS, Pazzaglia PJ, Mikalauskas K, Denicoff K. Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch NJ, Padgham C, Hughes MS, eds. Lithium in medicine and biology. Carnforth: Marius Press, 1993:71-84.
41. Coryell W, Solomon D, Leon et al. Lithium discontinuation and subsequent effectiveness. American Journal of Psychiatry 1998; 155:895-898.
42. Post RM, Leverich GS, Frye MA, Weiss SRB. Loss of drug efficacy (tolerance) during long-term prophylaxis. Biological Psychiatry 1997; 42: 296S-297S.
43. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998; 8:259-268.
44. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Journal of Clinical Psychiatry 1999; 60 (Suppl. 2):77-84.
45. Schou M. The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians. Journal of Affective Disorders 1998; 50:253-259.
46. Coryell W, Winokur G, Solomon D, Shea T, Leon A, Keller M. Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychological Medicine 1997; 2: 281-289.
47. Markar HR, Mander AJ. Efficacy of lithium prophylaxis in clinical practice. British Journal of Psychiatry 1989; 155:496-500.
48. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? American Journal of Psychiatry 1987; 144:1403-1411.
49. Pande A. Combination treatment in bipolar disorder. In: New pharmacotherapies session of 3rd International Conference on Bipolar Disorder at Pittsburgh, PA 17-19 June 1999. Copenhagen: Munksgaard.
50. Baldessarini RJ, Tondo L, Floris G, Rudas N. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. American Journal of Psychiatry 1997; 154:551-553.
51. Kupfer DJ, Frank E. Forty years of lithium treatment. Archives of General Psychiatry 1997: 54:14-15.
52. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. Journal of Clinical Psychiatry 1997; 58:470-478.
53. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine versus lithium in the treatment and prophylaxis of mania. British Journal of Psychiatry 1988; 153:198-204.
54. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatrica Scandinavica 1992; 85:114-118.
55. Berghofer A, Muller-Oerlinghausen B. Loss of efficacy after discontinuation of lithium. Biological Psychiatry 1997; 42:1S-297S.
56. Jerram TC, McDonald R. Plasma lithium control with particular reference to minimum effective levels. In: Johnson FN, Johnson S, eds. Lithium in medical practice. Baltimore: University Park Press, 1978:407-413.
57. Hullin RP. Minimum serum lithium levels for effective prophylaxis. In: Johnson FN, ed. Handbook of lithium therapy. Baltimore: University Park Press, 1980:243-247.
58. Maj M, Starace F, Nolfe G, Kemali D. Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: a prospective study. Pharmacopsychiatry 1986; 19:420-423.
59. Gelenberg AJ, Wojeik JD, Falk WE. Effects of lithium on the kidney. Acta Psychiatrica Scandinavica 1987; 75:29-34.
60. Placidi GF, Lenzi A, Lazzerini F et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomised, double-blind 3 year trial in 83 patients. Journal of Clinical Psychiatry 1986; 47:490-494.
61. Di Costanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatrica Scandinavica 1991; 83:456-459.
62. Solomon DA, Ryan CE, Keitner GI et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. Journal of Clinical Psychiatry 1997; 58:95-99.
63. Freeman MP, Stoll AL. Mood stabiliser combinations: a review of safety and efficacy. American Journal of Psychiatry 1998; 155:12-21.
64. Akiskal HS. Bipolar disorders. In: Karasu B, ed. The treatment of psychiatric disorders. Vol. 3. Washington, DC: American Psychiatric Association, 1989; 1925-40.
65. Schou M. The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatrica Scandinavica 1997; 95:361-363.
66. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. American Journal of Psychiatry 1998; 155:30-35.
67. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA. Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilising agents: therapeutic implications. Journal of Clinical Psychiatry 1999; 60 (Suppl. 2):27-39.
68. Zornberg GL, PopeHG Jr. Treatment of depression in bipolar disorder: new directions for research. Journal of Clinical Psychopharmacology 1993; 13:397-408.
69. Guille C, Shriver A, Demopulos C, Sachs G. Bupropion vs. desipramine in the treatment of bipolar depression. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999:33. Copenhagen: Munksgaard.
70. Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999. Copenhagen: Munksgaard.
71. Ascher J, Cookson J, Huffman R et al. Profile of antidepressant activity of lamotrigine in bipolar depression: results from a double-blind, placebo-controlled study. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999:23. Copenhagen: Munksgaard.
72. Laurenza A, Asnis G, Beaman M et al. A double-blind, placebo-controlled study supporting the efficacy of lamotrigine in unipolar depression. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999:39-40. Copenhagen: Munksgaard.
73. Anand A, Oren DA, Berman RM, Cappiello A, Charney DS. Lamotrigine treatment of lithium failure outpatient mania: a double-blind, placebo-controlled trial. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999:23. Copenhagen: Munksgaard.
74. Mallinger AG, Frank E, Barwell MM. Thase ME, Kupfer DJ. Effectiveness of traditional antidepressants is suboptimal in the depressed phase of bipolar disorder. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999:41. Copenhagen: Munksgaard.
75. Ghaemi SN, Sachs GS, Goodwin FK. Divalproex vs. lithium in the treatment of bipolar disorder: a naturalistic 1.7 year comparison. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999:31-32. Copenhagen: Munksgaard.
76. Brown ES, Suppes T, McElroy S et al. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999:25. Copenhagen: Munksgaard.
77. Roy-Chengappa KN, Rathore D, Levine J et al. Topiramate as add-on adjunctive treatment for patients with bipolar I or schizoaffective disorder-bipolar type disorder experiencing manic or mixed episodes. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999:27. Copenhagen: Munksgaard.
78. Hardoy MJ, Hardoy MC, Carta MG, Cabras PL. Gabapentin in the treatment of bipolar disorders. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA, June 17-19 1999:34. Copenhagen: Munksgaard.
79. Hoopes S. Lamotrigine in the treatment of bipolar depression and other affective disorders: clinical experience in 218 patients. In: Soares JC, Gershon S, eds. Abstract book of 3rd International Conference on Bipolar Disorder, Pittsburgh, PA. June 17-19 1999:35. Copenhagen: Munksgaard.